Set of oligonucleotide starters for determination of polymorphisms type SNP for CYP2C19*17(-3402CT), CYP2C19*3, ABCB1(C3435CT) and CYP2C19*2 genes and method for detection of disturbances in clopidogrel activity using the set of oligonucleotide starters

摘要

a set of primers revealed oligonukleotydowych for cytidine type snp for cyp2c19 * 17 genes (- 3402c t), cyp2c19 * 3, abcb1 (c3435c t) and cyp2c19 * 2, in the form of short fragments of nucleic acids, comprising the cyp2c19 and abcb1 gene sequences, including sequences oligonuk leotydu00f3w from 1 to 16, as defined in the list of sequencescontaining from 19 to 29 nucleotides complementary to the dna matrix. in addition, eight oligonukleotydowych primers defined in the list oligonukleotydu00f3w sequences from 9 to 16 different from each other in length, resulting from the addition to the 5 'end niehomologicznych sections polinukleotydowych, recorded the model general (cagt) n of different quantities, okay. well, u00f3rzeu0144 n.primers sequence defined in the list oligonukleotydu00f3w from 1 to 8, are intended to carry out amplification reactions, whose products include four fragments of different length, containing 4 marked polimorfizmy.the subject of the invention is also a method for detecting irregularities action of clopidogrel, which is that in the human genetic material, obtained by isolation genomowego dna from blood or saliva sample or with oral, is polimorfizmy type for cyp2c19 * 17 (snp - 3402c t), cyp2c19 * 3, abcb1 (c3435c t) and cyp2c19 * 2using a set of primers oligonukleotydowych presented in list oligonukleotydu00f3w sequence from 1 to 16, on the basis of polymorphism of genes assessed the potential risk of irregular effects of clopidogrel therapy, and in the case of at least j one of three cytidine: abcb1 (c3435c t), cyp2c19 * 2 or cyp2c19 * 3notes on action of clopidogrel resistance.